RT Journal Article SR Electronic T1 Towards integration of 64Cu-DOTA-Trasztusumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2+ breast cancer JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.06.10.20127639 DO 10.1101/2020.06.10.20127639 A1 Angela M. Jarrett A1 David A. Hormuth II A1 Vikram Adhikarla A1 Prativa Sahoo A1 Daniel Abler A1 Lusine Tumyan A1 Danial Schmolze A1 Joanne Mortimer A1 Russell C. Rockne A1 Thomas E. Yankeelov YR 2020 UL http://medrxiv.org/content/early/2020/06/12/2020.06.10.20127639.abstract AB While targeted therapies exist for human epidermal growth factor receptor 2 positive (HER2+) breast cancer, HER2+ patients do not always respond to therapy. We present the results of utilizing a biophysical mathematical model to predict tumor response for two HER2+ breast cancer patients treated with the same therapeutic regimen but who achieved different treatment outcomes. Quantitative data from magnetic resonance imaging (MRI) and 64Cu-DOTA-Trastuzumab positron emission tomography (PET) are used to estimate tumor density, perfusion, and distribution of HER2-targeted antibodies for each individual patient. MRI and PET data are collected prior to therapy, and follow-up MRI scans are acquired at a midpoint in therapy. Given these data types, we align the data sets to a common image space to enable model calibration. Once the model is parameterized with these data, we forecast treatment response with and without HER2-targeted therapy. By incorporating targeted therapy into the model, the resulting predictions are able to distinguish between the two different patient responses, increasing the difference in tumor volume change between the two patients by >40%. This work provides a proof-of-concept strategy for processing and integrating PET and MRI modalities into a predictive, clinical-mathematical framework to provide patient-specific predictions of HER2+ treatment response.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02827877Funding StatementThank you to the Baum Family and the Pacific Northwest Food Industries Circle. We thank the National Cancer Institute for support under award numbers U01CA174706, U24CA226110, U01CA142565, R01CA186193, P30CA033572; the Cancer Prevention Research Institute of Texas for funding through CPRIT RR160005, and the American Association of Physicists in Medicine for funding through the 2018 Research Seed Grant. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. T.E.Y. is a CPRIT Scholar in Cancer Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:City of Hope Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding authors on reasonable request.